Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: PBMTC Late Effects Consortium. For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This team has identified a subset of childhood Acute Lymphoblastic Leukemia (ALL) with specific genetic abnormalities in the leukemia cells (Ph-like ALL) that has poor survival. Some Ph-like ALL patients have genetic abnormalities that make their leukemia cells sensitive to a targeted therapy (dasatinib), which has many fewer side effects than chemotherapy. This consortium is using a COG clinical trial to help identify which children should respond to dasatinib, and then will add this targeted therapy to their chemotherapy to try to improve survival. Awarded at the University of Colorado and transferred to the Children's Hospital of Philadelphia. Funds administered by the Children's Hospital of Philadelphia.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This institution is a member of a research consortium which is being funded by St. Baldrick's:COG Targeted Therapy for ALL Consortium. For a description of this project, see the consortium grant made to the lead institution: Children's Hospital of Philadelphia, Philadelphia, PA.

This grant helps provide necessary resources to establish a database to further research to improve the health and quality of life of adolescent cancer survivors.

While most childhood cancer patients no longer die from cancer, young adult survivors of childhood cancer face enormously distressing side effects from their life-saving treatments. These include severe sexual and reproductive problems. Currently, no support is available to help educate young adult survivors about how to manage treatment-related sexual problems and fertility-related distress. This project aims to develop and deliver the first sexual health educational intervention for young adult survivors. This research can make a significantly positive impact on the quality of life for thousands of young adult cancer survivors who are struggling and in need of support.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

Children with cancer can often be successfully treated with chemotherapy drugs that can unfortunately damage the heart in the process. Development of an effective method to prevent this type of injury while curing the cancer is very important. This consortium's goal is to give children successfully cured of cancer the greatest chance of having a completely healthy life afterwards, free of treatment-related side effects. The study is to determine whether a drug called dexrazoxane, which appears to be safe and effective in adults in preventing chemotherapy-related heart injury, can be similarly safe and effective when used in children. Funds administered by Fred Hutchinson Cancer Research Center.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.